A nurse is assessing a 6-year-old child suspected of having growth hormone deficiency. Which assessment finding would be most indicative of this condition?

Growth hormone deficiency is characterized by short stature (height below 3rd percentile) with normal body proportions, distinguishing it from other growth disorders. Other options represent findings of obesity, advanced maturation, or precocious puberty.

Understanding the Condition
Growth hormone deficiency (GHD) in children primarily manifests as a deceleration of linear growth, leading to short stature. The pathophysiology involves inadequate secretion of growth hormone from the anterior pituitary gland, which normally stimulates the production of insulin-like growth factor-1 (IGF-1) and directly acts on the epiphyseal growth plates of long bones. When this axis is disrupted, skeletal growth slows significantly, but body proportions remain relatively normal. This is a key differentiator from skeletal dysplasias or genetic syndromes, which often present with disproportionate short stature.

Analysis of Assessment Findings
For a 6-year-old child with suspected GHD, the most indicative assessment finding is a height significantly below the expected range for age, coupled with normal body proportions. The diagnostic criteria for short stature is typically a height below the 3rd percentile on standardized growth charts. The preservation of normal body proportions occurs because the deficiency affects all long bones symmetrically, unlike conditions such as rickets or achondroplasia.

The provided evidence supports this clinical picture. In the case report by Meller et al., a 12-year-old female with newly diagnosed panhypopituitarism, which includes GHD, presented with a height at the 6th percentile and a severely reduced growth velocity of 0.75 cm/year ^[1]. This illustrates that even in late-onset presentations, the hallmark is a progressive drop-off in height percentiles, often falling below the 3rd percentile over time if untreated.

Why Other Options Are Incorrect
- Option 1: Height above the 97th percentile with increased arm span is characteristic of tall stature conditions, such as Marfan syndrome or homocystinuria, not a deficiency state.
- Option 2: While a delayed bone age is a classic finding in GHD, it is not the most indicative finding on initial physical assessment. The case report by Meller et al. noted a bone age consistent with chronological age at presentation, demonstrating that bone age delay can be variable and is a radiographic, not a physical assessment, finding ^[1]. The study by Gider et al. on somatrogon treatment tracked the bone age/chronological age (BA/CA) ratio as a marker of treatment response, confirming its relevance but secondary nature to the primary finding of short stature .
- Option 4: Early onset of secondary sexual characteristics with tall stature suggests precocious puberty. In precocious puberty, initial growth acceleration leads to tall stature in childhood, but paradoxically results in premature epiphyseal closure and a compromised final adult height. This is the opposite of the growth pattern in isolated GHD.

Clinical Application and Diagnostic Confirmation
When a nurse identifies a height below the 3rd percentile with normal body proportions, the next steps in the diagnostic process involve auxological monitoring and biochemical testing. A critical measurement is growth velocity, calculated over at least 6 months. A subnormal growth velocity, such as the 0.75 cm/year documented in the panhypopituitarism case, is a strong indicator of a pathological growth disorder ^[1]. Definitive diagnosis relies on GH stimulation testing and measurement of IGF-1 levels, which serve as a surrogate marker of GH secretion. The real-world study on somatrogon efficacy highlights the importance of monitoring IGF-1 levels and the BA/CA ratio to confirm the diagnosis and track the anabolic response to recombinant GH therapy .